PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases

Therapeutic strategies for epithelial ovarian cancers are evolving with the advent of immunotherapy, such as PD-L1 inhibitors, with encouraging results. However, little data are available on PDL-1 expression in ovarian cancers. Thus, we set out to determine the PD-L1 expression according to histolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Eymerit-Morin, Caroline, Ilenko, Anna, Gaillard, Thomas, Varinot, Justine, Compérat, Eva, Bendifallah, Sofiane, Darai, Emile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967270/
https://www.ncbi.nlm.nih.gov/pubmed/33728864
http://dx.doi.org/10.4081/ejh.2021.3185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967270/
https://www.ncbi.nlm.nih.gov/pubmed/33728864
http://dx.doi.org/10.4081/ejh.2021.3185

Ejemplares similares